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Advantage of recombinant von Willebrand factor for  
peri- operative management in paediatric acquired von 
Willebrand syndrome
Dear Editors,
A 2- year- old African American male child with pulmonary valve 
stenosis sustained a skull fracture and large epidural haemorrhage 
after a fall. He underwent multiple procedures over several days, all 
of which were complicated by postoperative bleeding. Past bleed-
ing history was significant for bleeding with eruption of new teeth. 
Family history was negative for bleeding manifestations. Laboratory 
workup prior to a planned cranioplasty revealed normal prothrombin 
time, activated partial thromboplastin time, thrombin time, fibrinogen, 
factor IX, factor XI and factor XIII (present by clot dissolution assay). 
Blood type was AB+. A von Willebrand factor (vWF) panel revealed 
elevated factor VIII (FVIII) of 333%, normal ristocetin cofactor activ-
ity (vWF:RCo) of 58% (normal range 50%- 150%) with vWF antigen 
(vWF:Ag) of 178% (normal range 50%- 150%; Table 1). The vWF:RCo/
vWF:Ag ratio was abnormally decreased to 0.33, consistent with ac-
quired von Willebrand syndrome (avWS), likely secondary to pulmo-
nic stenosis. Plasma von Willebrand multimer analysis revealed the 
absence or decreased abundance of the highest molecular weight 
multimers (HMWMs), but no definitely increased abundance of lower 
molecular weight vWF multimers, more characteristic of avWS than a 
congenital vWF defect. Although his vWF:RCo level was within a low- 
normal range, most guidelines suggest attaining a goal activity level 
of 100 IU/dL1 for surgical prophylaxis, particularly in major surgery.
Given the need for cranioplasty in the setting of avWS and significantly 
elevated factor VIII levels, there was concern about the use of traditional 
plasma- derived vWF concentrates (which all include FVIII in variable pro-
portions) and potential for increased thrombotic risk. Although thrombotic 
events are rare occurrences in patients with bleeding disorders, the risk 
in von Willebrand disease (vWD) does seem to be increased compared to 
that seen in haemophilia.2 Three of the four vWD patients with throm-
botic events within a systematic review whose FVIII level was measured 
had levels in excess of 200%.2 Given this, most guidelines recommend 
the following FVIII levels with replacement therapy and avoiding levels 
>100%- 200%.1,2 Thus, the decision was made to treat preoperatively 
with a recombinant vWF (rvWF) which does not contain FVIII (Vonvendi®; 
Shire, Dublin, Ireland) and may confer a lower risk of thromboembolic 
sequelae. The rvWF (80 IU/kg) was administered just prior to surgery. 
Adequate haemostasis was achieved with minimal blood loss. There was 
concern for an acute bleed due to a drop in haemoglobin on postoperative 
day 2, so he received an additional dose of 80 IU/kg of rvWF. This was 
later attributed to dilutional effects of intravenous fluid, and no evidence 
of bleeding was found by clinical assessment or imaging. The patient re-
covered well without complication.
Acquired von Willebrand syndrome is a rare entity with bleeding 
symptomatology similar to those seen in the inherited form of vWD. It 
is typically characterized by a negative family history, lack of prior bleed-
ing symptoms and older age. It most commonly occurs in patients with 
lymphoproliferative or myeloproliferative disease (63%), cardiovascular 
disease (21%), solid tumours (5%) or autoimmune disorders (2%). Within 
cardiovascular disease, where loss of HMWM is caused by increased shear 
stress, it has been reported to occur with aortic stenosis, pulmonary ste-
nosis, patent ductus arteriosus, ventricular and atrial septal defects and 
ventricular assist devices.3 The Risk of bleeding in patients with cardio-
pulmonary disorders has been associated with a VWF:RCo/VWF:Ag ratio 
of <0.7.4 There are no consistent guidelines for the treatment of aVWS 
likely due to its rarity. The efficacy of DDAVP is likely to be limited, and 
patients with cardiovascular disease have been reported to have the worst 
outcomes with its use with therapeutic responses only seen in 10%.5 
Additionally, DDAVP provided additional obstacles in our patient given the 
haemostatic challenges inherent to neurosurgery, his young age and risk of 
hyponatremia, and concern for further elevation of his FVIII.
Another complicating factor in our patient was his baseline ele-
vation in FVIII, likely secondary to a combination of an acute phase 
reaction to ongoing inflammation, non- O blood type6 and ethnicity.7 
Elevated plasma levels of FVIII have been associated with a dose- 
dependent increased thrombotic risk at levels >150 IU/dL.8 At least 
one case has been reported of avWS with elevated FVIII (to levels 
similar to our patient) treated with plasma- derived FVIII/vWF concen-
trate who went on to develop an embolic stroke.9 Given his severely 
elevated levels preoperatively, the use of a plasma- derived FVIII/
vWF concentrate was deemed to pose an unacceptable risk in terms 
of thrombosis. Recombinant vWF, in addition to the advantage of the 
absence of FVIII, also includes ultralarge and high- molecular weight 
multimers which are likely to be beneficial in the treatment of avWS. 
Additionally, most plasma- derived FVIII/VWF concentrates typically 
have a vWF:RCo/vWF:Ag ratio of <1, as opposed to >1 in rvWF.10 
This is likely to be advantageous in a disease where the vWF:RCo/vW-
F:Ag ratio is by very definition decreased. This case illustrates an ideal 
scenario in which rvWF may provide distinct advantages over plasma- 
derived FVIII/vWF concentrates. This is, to our knowledge, the first 
report of the use of rvWF in a paediatric patient, as well as the first 
reported case in avWS, since its approval in 2015. As yet, it has only 
been approved for on- demand treatment, with prophylactic Phase 3 
trials ongoing. Peri- operative treatment in this paediatric patient was 
efficacious, safe and tolerable. He did not develop any thrombotic 
complications, and no evidence of antibodies to vWF was observed.
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